Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Pharmacotherapy with L-DOPA remains the gold-standard therapy for PD, but is often limited by the development of the common side effect of L-DOPA-induced dyskinesia (LID), which can become debilitating. The only effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, Mitchell J., Flores, Andrew J., Ye, Tony, Smidt, Saskia I., Dollish, Hannah K., Stancati, Jennifer A., Farrell, Drew C., Parent, Kate L., Doyle, Kristian P., Besselsen, David G., Heien, Michael L., Cowen, Stephen L., Steece-Collier, Kathy, Sherman, Scott J., Falk, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518549/
https://www.ncbi.nlm.nih.gov/pubmed/32717354
http://dx.doi.org/10.1016/j.expneurol.2020.113413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518549/
https://www.ncbi.nlm.nih.gov/pubmed/32717354
http://dx.doi.org/10.1016/j.expneurol.2020.113413

Ejemplares similares